Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treat… Read more
Revelation Biosciences Inc (REVB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.144x
Based on the latest financial reports, Revelation Biosciences Inc (REVB) has a cash flow conversion efficiency ratio of -0.144x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.59 Million) by net assets ($11.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Revelation Biosciences Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Revelation Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Revelation Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Revelation Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MINERAL HILL INDUSTR.NEW
F:MLN
|
N/A |
|
Austin Metals Ltd
AU:AYT
|
-0.024x |
|
Millennium Pharmacon International
JK:SDPC
|
-0.062x |
|
Inca One Gold Corp
PINK:INCAF
|
-0.076x |
|
Orege S.A.
LSE:0QSU
|
N/A |
|
Debock Industries Limited
NSE:DIL
|
0.006x |
|
Rocky Mountain Liquor Inc
V:RUM
|
0.141x |
|
Forza X1 Inc
NASDAQ:FRZA
|
-0.075x |
Annual Cash Flow Conversion Efficiency for Revelation Biosciences Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Revelation Biosciences Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.71 Million | $-18.32 Million | -3.891x | -255.02% |
| 2023-12-31 | $6.65 Million | $-7.29 Million | -1.096x | +89.72% |
| 2022-12-31 | $1.05 Million | $-11.22 Million | -10.660x | -109.56% |
| 2021-12-31 | $-99.47K | $-11.09 Million | 111.497x | +176962.24% |
| 2020-12-31 | $3.41 Million | $-215.07K | -0.063x | +100.00% |
| 2019-12-31 | $-3.64K | $41.09 Million | -11293.568x | -9182593.30% |
| 2018-12-31 | $264.89 Million | $32.58 Million | 0.123x | -4.50% |
| 2017-12-31 | $188.28 Million | $24.25 Million | 0.129x | +87.38% |
| 2016-12-31 | $168.76 Million | $11.60 Million | 0.069x | -- |